{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:47:18Z","timestamp":1778600838385,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In 2010, the US Food and Drug Administration approved eribulin for the treatment of metastatic breast cancer (MBC). Since then, the treatment landscape has evolved with many new therapy classes, a more recent one being the small molecule inhibitors of phosphoinositide 3 kinase (PI3K). We sought to characterize the treatment patterns and clinical outcomes of patients with MBC who received eribulin following prior treatment with a PI3K inhibitor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study based on medical record review included MBC patients who initiated eribulin between March 2019 and September 2020 following prior treatment with a PI3K inhibitor was conducted. Patient demographics, treatment characteristics, and clinical outcomes were analyzed descriptively. Real-world progression-free survival (rwPFS) and overall survival (OS) were estimated from the initiation of eribulin therapy using Kaplan-Meier analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>82 eligible patients were included. Patients\u2019 median age at eribulin initiation was 62 years; 86.5% had hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative tumors. Eribulin was most often administered in the second or third line (82.9%) in the metastatic setting. Best overall response on eribulin was reported as complete or partial response in 72% of the patients. The median rwPFS was 18.9 months (95% confidence interval [CI], 12.4-not estimable); median OS was not reached. The estimated rwPFS and OS rates at 12 months were 63.3% (95% CI, 50.5\u201373.7) and 82.6% (95% CI, 72.4\u201389.3), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our real-world study suggests that eribulin may be a potential treatment option for MBC patients who fail a prior PI3K inhibitor.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-07080-1","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T09:01:52Z","timestamp":1707037312000},"page":"201-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer"],"prefix":"10.1007","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-036X","authenticated-orcid":false,"given":"Ravi K.","family":"Goyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingchuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Sluga-O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3677-6807","authenticated-orcid":false,"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,4]]},"reference":[{"issue":"3","key":"7080_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"7080_CR2","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: female breast cancer (2022) https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed May 26, 2022"},{"issue":"6","key":"7080_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","volume":"26","author":"AB Mariotto","year":"2017","unstructured":"Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 26(6):809\u2013815","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"7080_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475\u20131495","journal-title":"Ann Oncol"},{"issue":"9769","key":"7080_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K et al (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914\u2013923","journal-title":"Lancet"},{"issue":"4","key":"7080_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH et al (2020) Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(4):452\u2013478","journal-title":"J Natl Compr Canc Netw"},{"key":"7080_CR7","doi-asserted-by":"publisher","first-page":"175883591878645","DOI":"10.1177\/1758835918786451","volume":"10","author":"S Pernas","year":"2018","unstructured":"Pernas S, Tolaney SM, Winer EP, Goel S (2018) CDK4\/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol 10:1758835918786451","journal-title":"Ther Adv Med Oncol"},{"key":"7080_CR8","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.2147\/CMAR.S250632","volume":"12","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zhang Y, Pi H, Sheng Y (2020) Current therapeutic progress of CDK4\/6 inhibitors in breast cancer. Cancer Manag Res 12:3477\u20133487","journal-title":"Cancer Manag Res"},{"issue":"55","key":"7080_CR9","first-page":"552","volume":"17","author":"ML Telli","year":"2019","unstructured":"Telli ML, Gradishar WJ, Ward JH (2019) NCCN Guidelines updates: breast Cancer. J Natl Compr Canc Netw 17(55):552\u2013555","journal-title":"J Natl Compr Canc Netw"},{"key":"7080_CR10","doi-asserted-by":"publisher","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","volume":"30","author":"B Verret","year":"2019","unstructured":"Verret B, Cortes J, Bachelot T, Andre F, Arnedos M (2019) Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol 30:x12\u2013x20","journal-title":"Ann Oncol"},{"issue":"4","key":"7080_CR11","first-page":"342","volume":"12","author":"JJ Lee","year":"2015","unstructured":"Lee JJ, Loh K, Yap YS (2015) PI3K\/Akt\/mTOR inhibitors in breast cancer. Cancer Biol Med 12(4):342\u2013354","journal-title":"Cancer Biol Med"},{"issue":"4","key":"7080_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10555-010-9261-0","volume":"29","author":"CA Castaneda","year":"2010","unstructured":"Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM (2010) The phosphatidyl inositol 3-kinase\/AKT signaling pathway in breast cancer. Cancer Metastasis Rev 29(4):751\u2013759","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"7080_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","volume":"22","author":"O Martinez-Saez","year":"2020","unstructured":"Martinez-Saez O, Chic N, Pascual T, Adamo B, Vidal M, Gonzalez-Farre B et al (2020) Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res 22(1):45","journal-title":"Breast Cancer Res"},{"issue":"3","key":"7080_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N et al (2020) Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol 31(3):377\u2013386","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"7080_CR15","doi-asserted-by":"publisher","first-page":"viii709","DOI":"10.1093\/annonc\/mdy424.010","volume":"29","author":"F Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 F, Ciruelos EM, Rubovszky G, Campone M, Loibl S, Rugo HS et al (2018) Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial. Ann Oncol 29(suppl 8):viii709","journal-title":"Ann Oncol"},{"key":"7080_CR16","unstructured":"US Food and Drug Administration. Highlights of prescribing information: PIQRAY (alpelisib) (2019) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212526s006lbl.pdf. Accessed 12 Aug 2022"},{"issue":"2","key":"7080_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-020-05867-0","volume":"184","author":"S Kazmi","year":"2020","unstructured":"Kazmi S, Chatterjee D, Raju D, Hauser R, Kaufman PA (2020) Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat 184(2):559\u2013565","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"7080_CR18","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s12325-020-01613-6","volume":"38","author":"SS Mougalian","year":"2021","unstructured":"Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA (2021) Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv Ther 38(5):2213\u20132225","journal-title":"Adv Ther"},{"issue":"2","key":"7080_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"1","key":"7080_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207\u2013214","journal-title":"Cancer"},{"issue":"12","key":"7080_CR21","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1080\/03007995.2020.1835853","volume":"36","author":"I Chabot","year":"2020","unstructured":"Chabot I, Zhao Q, Su Y (2020) Systematic review of real-world effectiveness of eribulin for locally advanced or metastatic breast cancer. Curr Med Res Opin 36(12):2025\u20132036","journal-title":"Curr Med Res Opin"},{"key":"7080_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","volume":"96","author":"E Gobbini","year":"2018","unstructured":"Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M et al (2018) Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 96:17\u201324","journal-title":"Eur J Cancer"},{"issue":"1","key":"7080_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10549-020-05597-3","volume":"181","author":"M Van Mechelen","year":"2020","unstructured":"Van Mechelen M, Van Herck A, Punie K, Nevelsteen I, Smeets A, Neven P et al (2020) Behavior of metastatic breast cancer according to subtype. Breast Cancer Res Treat 181(1):115\u2013125","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07080-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:19:22Z","timestamp":1714569562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07080-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["7080"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07080-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,4]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Triangle Institute Institutional Review Board (IRB) granted this study waiver from full IRB review or informed consent from patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"RKG, KLD, and MSO are full-time employees of RTI Health Solutions, an independent nonprofit research organization, which was retained by Eisai Inc. to conduct the research that is the subject of this manuscript. Their compensation is unconnected to the studies on which they work. JZ is an employee of Eisai Inc. PAK received research support and\/or served as a consultant\/advisor for the following: Eisai Inc., Roche\/Genentech Amgen, Novartis, Macrogenics, Polyphor, Lilly, Pfizer, Sanofi, Bristol-Myer Squibb, H3 BioMedicine, Zymeworks Therapeutics, and AstraZeneca.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}}]}}